UK is no longer a draw to US pharma execs because of Brexit finds Alacrita


International life sciences consultancy Alacrita surveyed C-suite biotech executives in pre-eminent US companies and found that most feel that Brexit will make the UK a less attractive market. Anna Tobin reports

The Alacrita survey looked at how US pharmaceutical executives viewed the UK and the EU markets in the light of Brexit. It found that five to ten years after Brexit, over half, 52%, of US pharmaceutical executives feel that the UK will be a worse place for clinical trials and 69% feel that it will be a less attractive base for setting up a European head office.

The survey also reported that currently, the UK is the preferred EU country for clinical trials and also the top choice when it comes to choosing where to base an EU head office. It is second to Germany when it comes to the best country for launching a new pharmaceutical product.

There is information on how to set up a business in the EU in the Ready for Brexit Directory

How Ready for Brexit
can help you

  • We can help you redesign your business model and survive Brexit
  • Our consulting team have personal experience of operating before the Single Market and Customs Union
  • We know the issues and can help you solve your problems


We can help you deal
with key Brexit issues

Customs and Tariffs
Rules of Origin
Northern Ireland